Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

M. Procter · SciRah

Researcher profile · Semantic Scholar

M. Procter

Share profile

M. Procter — researcher profile on SciRah

h-index: 22
Works: 56
Citations: 12K

Most-cited papers

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.
M. Piccart-Gebhart, M. Procter, B. Leyland-Jones, A. Goldhirsch +28 more
2005New England Journal of Medicine5,182 citations Open access
Semantic Scholar
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
I. Smith, M. Procter, R. Gelber, S. Guillaume +20 more
2007The Lancet1,507 citations
Semantic Scholar
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
G. von Minckwitz, M. Procter, E. de Azambuja, D. Zardavas +14 more
2017New England Journal of Medicine1,206 citations Open access
Semantic Scholar
years ’ follow-up of trastuzumab after adjuvant chemotherapy in HER 2-positive early breast cancer : fi nal analysis of the HERceptin Adjuvant ( HERA ) trial
D. Cameron, M. Piccart-Gebhart, R. Gelber, M. Procter +12 more
2017856 citations
Semantic Scholar
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
L. Gianni, U. Dafni, R. Gelber, E. Azambuja +21 more
2011The Lancet Oncology644 citations
Semantic Scholar
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
T. Suter, M. Procter, D. van Veldhuisen, M. Muscholl +16 more
2007Journal of Clinical Oncology572 citations Open access
Semantic Scholar
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.
A. Goldhirsch, R. Gelber, M. Piccart-Gebhart, E. de Azambuja +21 more
2013The Lancet482 citations
Semantic Scholar
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
M. Piccart, M. Procter, D. Fumagalli, E. de Azambuja +24 more
2021Journal of Clinical Oncology304 citations Open access
Semantic Scholar
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.
M. Procter, Thomas M. Suter, E. de Azambuja, U. Dafni +16 more
2010Journal of Clinical Oncology257 citations
Semantic Scholar
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
E. de Azambuja, M. Procter, D. van Veldhuisen, D. Agbor-tarh +14 more
2014Journal of Clinical Oncology231 citations
Semantic Scholar
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.
M. Untch, R. Gelber, C. Jackisch, M. Procter +24 more
2008Annals of Oncology202 citations Open access
Semantic Scholar
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial.
M. Dowsett, M. Procter, W. McCaskill-Stevens, E. de Azambuja +10 more
2009Journal of Clinical Oncology198 citations Open access
Semantic Scholar
11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
D. Cameron, M. Piccart-Gebhart, R. Gelber, M. Procter +14 more
2017The Lancet118 citations Open access
Semantic Scholar
A Pooled Analysis of the Cardiac Events in the Trastuzumab Adjuvant Trials
E. de Azambuja, N. Pondé, M. Procter, P. Rastogi +9 more
2019Breast Cancer Research and Treatment63 citations Open access
Semantic Scholar
VP6-2022: Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years' follow-up
S. Loibl, J. Jassem, A. Sonnenblick, D. Parlier +16 more
2022Annals of Oncology54 citations Open access
Semantic Scholar
Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up
A. Goldhirsch, M. Piccart-Gebhart, M. Procter, E. de Azambuja +11 more
201246 citations
Semantic Scholar
years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial
A. Goldhirsch, R. Gelber, M. Procter, C. Jackisch +9 more
201345 citations
Semantic Scholar
Breast cancer, early stage
Tony S. K. Mok, L. Paz-Ares, Y.-L. Wu, S. Novello +496 more
201245 citations Open access
Semantic Scholar
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
O. Metzger-Filho, M. Procter, E. de Azambuja, B. Leyland-Jones +14 more
2013Journal of Clinical Oncology41 citations
Semantic Scholar
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update
S. Loibl, J. Jassem, A. Sonnenblick, D. Parlier +20 more
2024Journal of Clinical Oncology32 citations Open access
Semantic Scholar
HER2 staining intensity in HER2-positive disease: relationship with FISH amplification and clinical outcome in the HERA trial of adjuvant trastuzumab.
L. Zabaglo, O. Stoss, J. Rüschoff, D. Zielinski +7 more
2013Annals of Oncology29 citations Open access
Semantic Scholar
S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer
L. Gianni, A. Goldhirsch, R. Gelber, E. de Azambuja +10 more
200922 citations Open access
Semantic Scholar
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial
E. de Azambuja, E. Agostinetto, M. Procter, D. Eiger +17 more
2023ESMO Open21 citations Open access
Semantic Scholar
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial.
R. Gelber, X. V. Wang, B. Cole, D. Cameron +17 more
2022European Journal of Cancer19 citations Open access
Semantic Scholar
Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-pos
M. Piccart, M. Procter, D. Fumagalli, E. de Azambuja +24 more
2020General Session Abstracts19 citations
Semantic Scholar
LBA1 Adjuvant pertuzumab or placebo + trastuzumab + chemotherapy (P or Pla + T + CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years’ median follow-up
S. Loibl, M. Piccart, E. Clark, G. Viale +16 more
2025ESMO Open17 citations Open access
Semantic Scholar
APHINITY trial (BIG 4-11): A randomized comparison of chemotherapy (C) plus trastuzumab (T) plus placebo (Pla) versus chemotherapy plus trastuzumab (T) plus pertuzumab (P) as adjuvant therapy in patients (pts) with HER2-positive early breast cancer (EBC).
G. von Minckwitz, M. Procter, E. de Azambuja, D. Zardavas +14 more
201716 citations
Semantic Scholar
Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up
A. Goldhirsch, M. Piccart, M. Procter, E. de Azambuja +11 more
201215 citations Open access
Semantic Scholar
ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL
G. Romieu, H. Bonnefoi, J. Pierga, P. Kerbrat +29 more
201213 citations
Semantic Scholar
Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis
C. Jackisch, M. Piccart, R. Gelber, M. Procter +14 more
201611 citations
Semantic Scholar
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience
O. Metzger-Filho, E. de Azambuja, M. Procter, M. Krieguer +11 more
2015Breast Cancer Research and Treatment10 citations Open access
Semantic Scholar
Patient-reported function, health-related quality of life, and symptoms in APHINITY: pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer
J. Bines, E. Clark, C. Barton, E. Restuccia +13 more
2021British Journal of Cancer8 citations Open access
Semantic Scholar
Incidence and Management of Diarrhea With Adjuvant Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
J. Bines, M. Procter, E. Restuccia, G. Viale +11 more
2019Clinical Breast Cancer8 citations
Semantic Scholar
Trastuzumab after adjuvant chemotherapy in older patients - Reply
I. Smith, M. Procter, R. Gelber, M. Piccart-Gebhart
20077 citations
Semantic Scholar
Trastuzumab after adjuvant chemotherapy in older patients – Authors' reply
I. Smith, M. Procter, R. Gelber, M. Piccart-Gebhart
20076 citations
Semantic Scholar
Patient (pt)-reported function and symptoms in APHINITY: A randomized comparison of chemotherapy (C) + trastuzumab (H) + placebo (Pla) versus C + H + pertuzumab (P) as adjuvant therapy in pts with HER2-positive early breast cancer (EBC).
J. Baselga, J. Petersen, E. Clark, C. Barton +14 more
20185 citations
Semantic Scholar
Timelines to initiate a phase III trial across the globe: a sub-analysis of the APHINITY trial
M. Franzoi, M. Procter, C. Twelves, N. Pondé +8 more
2022ecancermedicalscience4 citations Open access
Semantic Scholar
Meta-analysis of the cardiac events in the adjuvant trastuzumab trials.
E. de Azambuja, N. Pondé, M. Procter, P. Rastogi +8 more
20184 citations
Semantic Scholar
Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial.
E. de Azambuja, Daniel Eiger, M. Procter, N. Pondé +16 more
2021Journal of Clinical Oncology2 citations
Semantic Scholar
Imputing missing quality of life data as covariate in survival analysis of the International Breast Cancer Study Group Trials VI and VII
M. Procter, C. Robertson
2019Communications in statistics. Simulation and computation2 citations Open access
Semantic Scholar
Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial.
E. de Azambuja, M. Procter, D. van Veldhuisen, D. Agbor-tarh +14 more
20132 citations
Semantic Scholar
Abstract PD10-01: Impact of HER2 Staining Intensity on Prognosis and Treatment Benefit of Adjuvant Trastuzumab Given after Chemotherapy: the HERA Trial Experience
Lila Zabaglo, O. Stoss, J. Rueschoff, D. Zielinski +6 more
20102 citations
Semantic Scholar
Assessment of trastuzumab-related cardiac dysfunction in the Herceptin Adjuvant (HERA) Trial with 3.6 years median follow- up.
M. Procter, T. Suter, E. de Azamuja, S. Muehlbauer +4 more
2009Journal of Clinical Oncology2 citations
Semantic Scholar
P110 Cardiac side effects in the HERceptin Adjuvant, (HERA) trial
T. Suter, M. Procter, D. van Veldhuisen, M. Muscholl +3 more
20072 citations
Semantic Scholar
Abstract PS7-21: Timelines to initiate an adjuvant phase III trial across the globe: A sub-analysis of the APHINITY trial
M. Franzoi, M. Procter, O. Emond, D. Parlier +8 more
20211 citations
Semantic Scholar
Abstract P1-13-07: Incidence and management of diarrhea with adjuvant pertuzumab and trastuzumab in HER2-Positive breast cancer
J. Bines, E. de Azambuja, D. Zardavas, M. Procter +11 more
20181 citations
Semantic Scholar
Influence of missing explanatory variables and longitudinal assessments in breast cancer clinical trials
M. Procter
20161 citations
Semantic Scholar
Abstract P2-15-04: Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: The HERA trial experience
O. Metzger, M. Procter, E. de Azambuja, M. Krieguer +2 more
20131 citations
Semantic Scholar
19P Her2 Extracellular Domain Levels in Patients With Her2-Positive Early Breast Cancer Experiencing Disease Progression: Case-Control Comparison of Samples from the Hera Study
M. Dowsett, M. Procter, E. de Azambuja, M. Scullion +2 more
20121 citations Open access
Semantic Scholar
Abstract PS10-01: 6-year absolute invasive disease-free survival (IDFS) benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A STEPP analysis of the APHINITY (BIG 4-11) trial
R. Gelber, X. V. Wang, B. Cole, D. Cameron +17 more
2021Poster Session Abstracts0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Gelber×35
Invite
R. Gelber — researcher profile on SciRah
E. de Azambuja×33
Invite
E. de Azambuja — researcher profile on SciRah
M. Piccart-Gebhart×23
Invite
M. Piccart-Gebhart — researcher profile on SciRah
J. Baselga×20
Invite
J. Baselga — researcher profile on SciRah

×16

Invite

I. Smith — researcher profile on SciRah

Invite

J. Bines — researcher profile on SciRah

B. Leyland-Jones×15

Invite

B. Leyland-Jones — researcher profile on SciRah

Invite

R. Bell — researcher profile on SciRah

C. Jackisch×15

Invite

C. Jackisch — researcher profile on SciRah

Invite

M. Dowsett — researcher profile on SciRah

Invite

M. Untch — researcher profile on SciRah

Invite

D. Cameron — researcher profile on SciRah